Entera Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Entera Bio’s promising developments in their oral GLP-2 and EB613 programs. The company has presented encouraging preclinical data for their oral GLP-2 analog, developed in collaboration with OPKO Health, which could offer significant advantages over existing therapies for Short Bowel Syndrome. This oral candidate could potentially provide greater convenience and better compliance for patients compared to the current treatment, Gattex, which requires daily injections.
Additionally, Entera Bio’s EB613, an oral anabolic tablet for osteoporosis, has shown positive results in increasing bone mineral density and improving bone strength in clinical studies. The data presented at a recent conference demonstrated significant improvements in bone parameters, suggesting that EB613 could rapidly enhance bone health and fracture resistance. These promising developments in Entera Bio’s pipeline contribute to the positive outlook and the Buy rating assigned by Selvaraju.